Lupin’s - US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Fenofibric Acid Delayed-Release Capsules 45 mg and 135 mg. The company had earlier received final approval from the USFDA for the same. Trilipix Delayed-Release Capsules 45 mg & 135 mg strengths had annual US sales of approximately $449.5 million, as per IMS MAT Sep, 2013.
Lupin’s Fenofibric Acid Delayed-Release Capsules 45 mg and 135 mg are the generic equivalent of AbbVie Inc.’s Trilipix Delayed-Release Capsules 45 mg & 135 mg strengths are indicated as co-administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: